Skip to search formSkip to main contentSkip to account menu

phosphatidylinositol 3-kinase complex, class IA

Known as: class IA PI3K complex, phosphatidylinositol 3-kinase complex location, class IA, phosphoinositide 3-kinase complex, class IA 
A class I phosphatidylinositol 3-kinase complex that possesses 1-phosphatidylinositol-4-phosphate 3-kinase activity; comprises a catalytic class IA… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Background: CDK4/6 inhibitors in combination with antiestrogens are approved for the treatment of ER+ advanced breast cancer… 
2015
2015
........................................................................................................................................vi Table of contents.........................................................................................................................vii List of figures..............................................................................................................................xiii List of tables...............................................................................................................................xvi Chapter 1: Introduction ..................................................................................................................................... 1 1.1 Signal Transduction ................................................................................................................................... 1 1.2 Shc General...........................................................................................................................5 1.3 ShcA .................................................................................................................................................................. 6 1.3.1 Isoforms ....................................................................................................................................................... 6 1.3.2 Domain architecture ............................................................................................................................... 6 1.3.2.1 PTB domain ............................................................................................................................................ 6 1.3.2.2 CH1 domain ............................................................................................................................................ 8 1.3.2.3 SH2 domain ............................................................................................................................................ 9 1.3.2.4 CH2 domain ......................................................................................................................................... 10 1.3.2.5 Cytochrome C binding region ....................................................................................................... 11 viii 1.4 ShcA in signaling ....................................................................................................................................... 11 1.4.1 Mitogen-activated protein kinase (MAPK) signaling .............................................................. 11 1.4.1.1 Extracellular signal-regulated kinase (Erk) pathway ......................................................... 11 1.4.1.2 c-Jun N-terminal kinase pathway.................................................................................13 1.4.2 Phosphatidylinositol-4, 5-bisphosphate 3-kinase (PI3K) pathway..............................13 1.4.3 Mammalian target of rapamycin (mTOR) signaling ................................................................ 14 1.4.4 Redox signaling ...................................................................................................................................... 14 1.5 ShcA in Development............................................................................................................15 1.5.1 Cardiovascular system ........................................................................................................................ 15 1.5.2 Muscular tissue ...................................................................................................................................... 16 1.5.3 Immune system ..................................................................................................................................... 17 1.5.4 Neuronal tissue ...................................................................................................................................... 18 1.6 ShcA in human disease ........................................................................................................................... 20 1.6.1 Neurodegenerative disease .............................................................................................................. 20 1.6.2 Cancer ........................................................................................................................................................ 20 1.6.2.1 Breast Cancer ...................................................................................................................................... 20 1.7 Summary ....................................................................................................................................................... 24 1.8 Research objectives .................................................................................................................................. 25 Chapter 2: Materials and Methods ............................................................................................................. 26 2.1 Materials ....................................................................................................................................................... 26 ix 2.1.1 Chemicals .................................................................................................................................................. 26 2.1.2 Enzymes and growth factor ............................................................................................................... 26 2.1.3 Kits and other materials ...................................................................................................................... 26 2.1.4 Bacterial cell culture reagents .......................................................................................................... 27 2.1.5 Mammalian cell culture reagents..................................................................................................... 28 2.1.5 Composition of complete growth media ....................................................................................... 28 2.1.6 Antibodies..........................................................................................................................29 2.1.7 Plasmids ..................................................................................................................................................... 30 2.1.8 Stock solutions and buffers ................................................................................................................ 31 2.2 Molecular biology ...................................................................................................................................... 37 2.2.1 Restriction cloning................................................................................................................................. 37 2.2.2 Mutagenesis ............................................................................................................................................. 39 2.2.3 Transformation ....................................................................................................................................... 40 2.2.4 DNA extraction ........................................................................................................................................ 40 2.2.5 Generation of competent cells .......................................................................................................... 40 2.3 Cell biological methods ........................................................................................................................... 41 2.3.1 Maintenance of mammalian cell lines ............................................................................................ 41 2.3.2 Transfection of mammalian cell lines ............................................................................................ 41 2.3.3 Lentiviral infection of mammalian cell lines ............................................................................... 41 2.3.4 Generation of stable cell lines ........................................................................................................... 42 x 2.3.5 Preparation and recovery of frozen stocks of mammalian cells....................................42 2.3.6 Fluorescence lifetime imaging microscopy (FLIM) .................................................................. 42 2.3.7 Immunoprecipitation ........................................................................................................................... 43 2.4 Protein expression and purification ................................................................................................... 43 2.4.3 GST-tagged ShcPTB and ShcSH2 proteins .................................................................................... 44 2.4.4 His-tagged Erk2 protein ...................................................................................................................... 45 2.4.5 GST-tagged Erk2 ..................................................................................................................................... 45 2.4.6 GST-tagged Pin1 proteins ................................................................................................................... 45 2.4.7 His-tagged Pin1 ....................................................................................................................................... 45 2.4.8 GFP-14-3-3 zeta ...................................................................................................................................... 46 2.4.9 GST-tagged 14-3-3 Tau and Epsilon proteins ............................................................................. 46 2.4.10 HA-tagged Nedd4 ................................................................................................................................ 
2014
2014
Cancer research has seen tremendous changes over the past decade. Fast progress in sequencing technology has afforded us with… 
2013
2013
GM3, the simplest ganglioside, regulates cell proliferation, migration, and invasion by influencing cell signaling at themembrane… 
2012
2012
Autophagy is an evolutionarily conserved, multi-step lysosomal degradation process in which a cell degrades its own long-lived… 
2012
2012
El melanoma metastasico es un modelo de tumor especialmente agresivo y resistente a inmuno, radio y quimioterapia. La pobre… 
2007
2007
Received 2 November 2006 Revised 1 March 2007 Accepted 5 March 2007 The phosphatidylinositol (PtdIns) 3-kinase Vps34p of the… 
2007
2007
In silico studies of the effect of phenolic compounds from grape seed extracts on the activity of phosphoinositide 3-kinase (PI3K… 
2006
2006
7532 Background: Mantle Cell Lymphoma (MCL) is characterized by t(11;14) resulting in over expression of cyclin D1, a member of… 
2002
2002
Fission yeast Rad3 is a member of a family of phosphoinositide 3-kinase -related kinases required for the maintenance of genomic…